Evidence map›Paper›PMID 36443039›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2022

[Single-Center Experience of Treating Chronic Limb-Threatening Ischemia of Lower Limbs Combined with Diabetes].

Xin Luo, Ke Huang, Bin Huang, Xin Wen, Yi-Yuan Li, Ji-Chun Zhao, Xing-Wu Ran, Da-Wei Chen, Yun Gao, Xi-Yang Chen and 2 more

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Xin LuoDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Ke HuangWest China School of Clinical Medicine, Sichuan University, Chengdu 610041, China.
Bin HuangDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Xin WenDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Yi-Yuan LiDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Ji-Chun ZhaoDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Xing-Wu RanInnovation Center for Wound Repair, Diabetic Foot Care Center, Department of Endocrinology and Metabolism, , West China Hospital, Sichuan University, Chengdu 610041, China.
Da-Wei ChenInnovation Center for Wound Repair, Diabetic Foot Care Center, Department of Endocrinology and Metabolism, , West China Hospital, Sichuan University, Chengdu 610041, China.
Yun GaoInnovation Center for Wound Repair, Diabetic Foot Care Center, Department of Endocrinology and Metabolism, , West China Hospital, Sichuan University, Chengdu 610041, China.
Xi-Yang ChenDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiao-Jiong DuDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Qiang GuoDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To summarize our hospital's single-center experience of and reflections on the treatment of chronic limb-threatening ischemia (CLTI) of lower limbs combined with diabetes in the past 5 years. Methods: We retrospectively analyzed cases of lower limb CLTI combined with diabetes diagnosed at our hospital from March 2017 to June 2021. The baseline data, surgical information, and follow-up results of the patients were collected. The primary outcome indicator was the patency rate of lower limb target artery within 1 year post-op, and the secondary indicators were the reoperation rate within 1 year post-op and the amputation rate within 1 year post-op. Results: A total of 89 patients with lower limb CLTI combined with diabetes were included in the study. A total of 85 patients underwent percutaneous transluminal angioplasty and the operation of 7 patients ended in failure, with the operation success rate reaching 91.76% (78/85). Three patients underwent femoral popliteal artery bypass grafting with artificial blood vessels and one patient underwent iliac femoral artery bypass grafting with artificial blood vessels, with the success rate of the operations reachign 100% (4/4). Among 78 patients who successfully underwent percutaneous transluminal angioplasty, the median follow-up time was 33 months (13, 64). Two patients died within one year after operation, with the post-op one-year survival rate being 97.44% (76/78). The post-op 1-year reoperation rate was 19.23% (15/78), the 1-year target vascular patency rate (deaths not included) was 85.53% (65/76), and the 1-year amputation rate was 3.85% (3/78). Among the patients who underwent bypass surgery, the follow-up period was 13-48 months. No thrombosis in or re-occlusion of the artificial blood vessels were observed during the follow-up period, and the artificial blood vessels remained unoccluded. Conclusion: Transluminal angioplasty has a relatively ideal rate of postoperative vascular patency. In addition, it is a minimally invasive procedure involving low perioperative risks and is performed under local anesthesia. Therefore, it can be used as the preferred treatment for patients with CLTI. On the other hand, bypass surgery has good long-term patency rate, but it involves higher perioperative risks and the procedure is more invasive. Therefore, bypass surgery can be used as an alternative when transluminal angioplasty ends in failure.

Indexed as

Blood SubstitutesDiabetes MellitusChronic Limb-Threatening IschemiaHumansLower ExtremityRetrospective StudiesBlood SubstitutesBypass surgeryChronic limb-threatening ischemiaDiabetes mellitusPercutaneous transluminal angioplasty

Identifiers

PMID36443039
PMCPMC10408967
OpenAlexW4310463256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.